Top

Published in:

01-10-2020 | Hypersensitivity Pneumonitis | IM - ORIGINAL

Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features

Authors: Nicola Lanzarone, Francesco Gentili, Valerio Alonzi, Laura Bergantini, Miriana d’Alessandro, Paola Rottoli, Rosa Metella Refini, Maria Pieroni, Lucia Vietri, Francesco Bianchi, Maria Antonietta Mazzei, Luca Volterrani, Anna Perrone, Paolo Cameli, Elena Bargagli, Piersante Sestini

Published in: Internal and Emergency Medicine | Issue 7/2020

Abstract

Chronic hypersensitivity pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from inhalation of different organic substances and chemical compounds determining an inflammatory and immunological response in sensitized individuals. KL-6, a human mucin protein expressed by type 2 pneumocytes, has been proposed as a prognostic biomarker of cHP. Assessment of usefulness KL-6 in ILD has been investigated primarily in Asiatic population. The aim of this study was to evaluate clinical utility of KL-6 in serum and bronchoalveolar lavage (BAL). In this study, we retrospectively analysed clinical, radiological and immunological data of a cohort of 42 patients affected by cHP: KL-6 concentrations were collected from serum and BAL. KL-6 clinical value was assessed through the analysis of association between KL-6 concentrations and clinical, functional, immunological and radiological features. KL-6 serum concentration results increased in 28/34 patients (82%). A positive direct correlation was observed between KL-6 concentrations in BAL and serum (r = 0.62, p < 0.05). In our study population we found that patients with extensive presence of ground glass opacities and centrilobular nodules at high-resolution computed tomography (HRCT) showed the highest concentrations of KL-6 in BAL and a predominantly CD3+ CD8+ BAL lymphocytosis. BAL lymphocytosis and KL-6 concentrations showed a direct correlation. BAL KL-6, a result of alveolar damage, caused in cHP by CD3+ CD8+ mediated flogosis and suggested by radiological evidence of ground-glass opacities and centrilobular nodules, can be considered a useful biomarker to assess, along with BAL cellular analysis and HRCT findings, disease activity.

Available only for authorised users

Lacasse Y, Selman M, Costabel U et al (2003) Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168(8):952–958. https://doi.org/10.1164/rccm.200301-137OCCrossRefPubMed

Mazzei MA, Sartorelli P, Bagnacci G et al (2019) Occupational lung diseases: underreported diagnosis in radiological practice. Semin Ultrasound CT MRI 40(1):36–50. https://doi.org/10.1053/J.SULT.2018.10.019CrossRef

Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR (2017) Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med 196(6):690–699. https://doi.org/10.1164/rccm.201608-1675PPCrossRefPubMedPubMedCentral

Sartorelli P, d'Hauw G, Spina D, Volterrani L, Mazzei MA (2020) A case of hypersensitivity pneumonitis in a worker exposed to terephthalic acid in the production of polyethylene terephthalate. Int J Occup Med Environ Health. 33(1):119–123. https://doi.org/10.13075/ijomeh.1896.01465CrossRefPubMed

Vasakova M, Morell F, Walsh S, Leslie K, Raghu G (2017) Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med 196(6):680–689. https://doi.org/10.1164/rccm.201611-2201PPCrossRefPubMed

Elicker BM, Jones KD, Henry TS, Collard HR (2016) Multidisciplinary approach to hypersensitivity pneumonitis. J Thorac Imaging 31(2):92–103. https://doi.org/10.1097/RTI.0000000000000186CrossRefPubMed

Wuyts WA, Dooms C, Verleden GM (2013) The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 187(7):777–777. https://doi.org/10.1164/ajrccm.187.7.777CrossRefPubMed

Richerson HB, Bernstein IL, Fink JN et al (1989) Guidelines for the clinical evaluation of hypersensitivity pneumonitis: report of the subcommittee on hypersensitivity pneumonitis. J Allergy Clin Immunol 84(5):839–844. https://doi.org/10.1016/0091-6749(89)90349-7CrossRefPubMed

Fenoglio C-M, Reboux G, Sudre B et al (2007) Diagnostic value of serum precipitins to mould antigens in active hypersensitivity pneumonitis. Eur Respir J 29(4):706–712. https://doi.org/10.1183/09031936.00001006CrossRefPubMed

10.

Cormier Y, Bélanger J, Tardif A, Leblanc P, Laviolette M (1986) Relationships between radiographic change, pulmonary function, and bronchoalveolar lavage fluid lymphocytes in farmer’s lung disease. Thorax 41(1):28–33. https://doi.org/10.1136/thx.41.1.28CrossRefPubMedPubMedCentral

11.

Hanak V, Golbin JM, Hartman TE, Ryu JH (2008) High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 134(1):133–138. https://doi.org/10.1378/CHEST.07-3005CrossRefPubMed

12.

Morisset J, Johannson KA, Jones KD et al (2018) Identification of diagnostic criteria for chronic hypersensitivity pneumonitis. An international modified Delphi Survey. Am J Respir Crit Care Med. 197(8):1036–1044. https://doi.org/10.1164/rccm.201710-1986OCCrossRefPubMedPubMedCentral

13.

Gruden JF, Webb WR, Warnock M (1994) Centrilobular opacities in the lung on high-resolution CT: diagnostic considerations and pathologic correlation. Am J Roentgenol 162(3):569–574. https://doi.org/10.2214/ajr.162.3.8109498CrossRef

14.

Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J (2008) Fleischner society: glossary of terms for thoracic imaging. Radiology 246(3):697–722. https://doi.org/10.1148/radiol.2462070712CrossRefPubMed

15.

Buschman DL, Gamsu G, Waldron JA, Klein JS, King TE (1992) Chronic hypersensitivity pneumonitis: use of CT in diagnosis. Am J Roentgenol 159(5):957–960. https://doi.org/10.2214/ajr.159.5.1414806CrossRef

16.

Abbritti M, Mazzei MA, Bargagli E et al (2012) Utility of spiral CAT scan in the follow-up of patients with pulmonary Langerhans cell histiocytosis. Eur J Radiol 81(8):1907–1912. https://doi.org/10.1016/J.EJRAD.2011.04.018CrossRefPubMed

17.

Sergiacomi G, Cicciò C, Boi L et al (2010) Ground-glass opacity: high-resolution computed tomography and 64-multi-slice computed tomography findings comparison. Eur J Radiol 74(3):479–483. https://doi.org/10.1016/J.EJRAD.2009.03.034CrossRefPubMed

18.

Nobuoki K, Seishi K, Yukikazu A, Hirofumi F, Michio Y, Mitoshi A (1989) New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 96(1):68–73. https://doi.org/10.1378/CHEST.96.1.68CrossRef

19.

Ohnishi H, Yokoyama A, Kondo K et al (2002) Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165(3):378–381. https://doi.org/10.1164/ajrccm.165.3.2107134CrossRefPubMed

20.

Bergantini L, Bianchi F, Cameli P et al (2019) Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers 2019:1–7. https://doi.org/10.1155/2019/8565423CrossRef

21.

Bergantini L, Bargagli E, Cameli P et al (2019) Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib. Respir Investig 57(3):290–291. https://doi.org/10.1016/j.resinv.2019.02.001CrossRefPubMed

22.

Ishikawa N, Hattori N, Yokoyama A, Kohno N (2012) Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 50(1):3–13. https://doi.org/10.1016/J.RESINV.2012.02.001CrossRefPubMed

23.

Okamoto T, Fujii M, Furusawa H, Tsuchiya K, Miyazaki Y, Inase N (2015) The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med 109(12):1576–1581. https://doi.org/10.1016/j.rmed.2015.10.005CrossRefPubMed

24.

Kohno N, Awaya Y, Oyama T et al (1993) KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 148(3):637–642. https://doi.org/10.1164/ajrccm/148.3.637CrossRefPubMed

25.

Bargagli E, Margollicci M, Perrone A et al (2007) Chitotriosidase analysis in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis 24(1):59–64

26.

Oberstein A, von Zitzewitz H, Schweden F, Müller-Quernheim J (1997) Non invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 14(1):65–72PubMed

27.

Drent M, De VJ, Lenters M et al (2003) Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 13(11):2462–2471. https://doi.org/10.1007/s00330-003-1965-xCrossRefPubMed

28.

Daimon T, Tajima S, Oshikawa K, Bando M, Ohno S, Sugiyama Y (2005) KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Intern Med. 44(8):811–817. https://doi.org/10.2169/internalmedicine.44.811CrossRefPubMed

29.

Okada F, Ando Y, Yoshitake S et al (2007) Clinical/pathologic correlations in 553 patients with primary centrilobular findings on high-resolution CT scan of the thorax. Chest 132(6):1939–1948. https://doi.org/10.1378/chest.07-0482CrossRefPubMed

30.

Hirschmann JV, Pipavath SNJ, Godwin JD (2009) Hypersensitivity pneumonitis: a historical, clinical, and radiologic review. Radiographics 29(7):1921–1938. https://doi.org/10.1148/rg.297095707CrossRefPubMed

31.

Selman M, Pardo A, King TE Jr. (2012) Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 186(4):314–324. https://doi.org/10.1164/rccm.201203-0513CICrossRefPubMed

Title: Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features
Authors: Nicola Lanzarone
Francesco Gentili
Valerio Alonzi
Laura Bergantini
Miriana d’Alessandro
Paola Rottoli
Rosa Metella Refini
Maria Pieroni
Lucia Vietri
Francesco Bianchi
Maria Antonietta Mazzei
Luca Volterrani
Anna Perrone
Paolo Cameli
Elena Bargagli
Piersante Sestini
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Hypersensitivity Pneumonitis
Biomarkers
Published in: Internal and Emergency Medicine / Issue 7/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02281-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2020

Epidemiology of right ventricular systolic dysfunction in patients with sepsis and septic shock in the emergency department

The HEART score as a prognostic tool for revascularization: comment

Novel biomarkers to assess the risk for acute coronary syndrome: beyond troponins

Bronchoalveolar lavage findings in severe COVID-19 pneumonia

Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma

Correction to: Management of chronic ischemic heart disease into internal medicine and geriatric departments in Italy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials